Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology firm, announced its participation in two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology firm, announced its participation in two upcoming virtual investor conferences. Dr. Alon Seri-Levy, CEO, will present at the Solebury Trout 2021 Virtual Investor Conference from January 11-15, 2020, with on-demand access available. Additionally, CFO Gilad Mamlok will speak at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2020, accessible to participants. Sol-Gel is focused on developing topical drugs for skin diseases, including treatments for acne and rosacea.
Details
News Market Reaction – SLGL
The recorded move for SLGL in the trading session of this news was +3.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present an overview of the Company and provide a business update at the following virtual investor conferences.
| Solebury Trout 2021 Virtual Investor Conference | ||
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer | |
| Date: | January 11-15, 2020 | |
| Access: | Available on demand at the following Link | |
| H.C. Wainwright BioConnect 2021 Virtual Conference | ||
| Speakers: | Gilad Mamlok, Chief Financial Officer | |
| Date: | January 11-14, 2020 | |
| Access: | Available on demand to conference participants. | |
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of Twyneo (benzoyl peroxide and tretinoin) cream, under investigation for the treatment of acne vulgaris, and Epsolay®, under investigation for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Michael Levitan
Solebury Trout
+1-646-378-2920
mlevitan@soleburytrout.com
Source: Sol-Gel Technologies Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.